기사 (362건) 리스트형 웹진형 타일형 Health ministry to reimburse Duekaro, remove limitations on Irribow, exclude Jext Health ministry to reimburse Duekaro, remove limitations on Irribow, exclude Jext Boryung Pharmaceutical has completed preparations for the launch of Duekaro, which is the three-drug combination based on domestic drug Kanarb(fimasartan) and consisting of ARB + CCB + statin.The Ministry of Health and Welfare preannounced the revision of the details of application criteria and meth e_newsmp | 2020-01-26 15:17 Hanmi, Outpatient prescriptions close to 600B Hanmi, Outpatient prescriptions close to 600B Hanmi Pharmaceutical is expected to reach the 600 billion won mark for the first time in the outpatient prescription market.According to UBIST, Hanmi Pharm recorded cumulative prescriptions of 556.3 billon won until last November, exceeding the annual prescription record of 551.6 billon won i e_newsmp | 2020-01-15 12:19 Biogen, Amgen, Novo Nordisk shine in 2019 Biogen, Amgen, Novo Nordisk shine in 2019 In 2019, Biogen emerged as a new star with Spinraza.According to IQVIA, Biogen posted sales of 10 billion in the first quarter(2019 2Q) immediately after reimbursement of Spinraza, followed by 20 billion in the second quarter(3Q), achieving 30 billion in sales during two quarters.Amgen, whose e_newsmp | 2020-01-14 18:08 ARB combo sales growth slower - single agent growth improved ARB combo sales growth slower - single agent growth improved In the second half of last year, the ARB single agent and combination drug market was showing a completely different picture, drawing attention.After the detection of carcinogenic substances in valsartan generic raw material, that emerged in July 2018, the growth of original drug had been rem e_newsmp | 2020-01-14 18:05 처음처음이전이전이전111213141516171819끝끝